Liver resection and ablation for metastatic XXXX .

@entity1 @entity6687 @entity1636 @entity409
BACKGROUND: @entity1636 ( @entity1636 ) is a rare disease without effective chemotherapy treated most appropriately with resection. The aim of this study was to evaluate our experience with liver resection for metastatic @entity1636 . METHODS: This study is a retrospective review of @entity1 who underwent liver resection or radiofrequency ablation (RFA) for @entity1636 from 1979 to 2009. RESULTS: A total of 27 @entity1 were identified. Of the 27, 19 underwent liver resection. Of the 19, 10 had a single @entity409 , and 18 of 19 were rendered free of @entity409 , although only 11 of 19 were rendered completely free of disease because of @entity6687 ( @entity6687 ). Of the 19, 13 had synchronous @entity6687 . Also, 6 of 17 remained disease free in the liver at a median follow-up of 6.2 years (status of 2 of 19 was unknown). Of the 27 @entity1 , 8 underwent RFA, 7 of 8 became free of @entity409 , and 5 of 7 had @entity6687 . No @entity1 responded to prior chemotherapy. Median overall survival and survival of @entity1 who underwent liver resection or RFA were both 1.9 years (0.2-12 + years); 5-year actuarial survivals were 29% and 29%, respectively. Disease-free interval (DFI) greater than 9 months from primary resection was associated with longer survival (median 4.1 vs 0.9 years; P = .013). CONCLUSIONS: This study is a tertiary institution series of liver resection and RFA for @entity1636 . Given the lack of effective systemic treatment options and the safety of resection and ablation, liver resection or RFA may be considered in selected @entity1 with @entity1636 metastatic to the liver especially with a long DFI.
